Should We Be Concerned About Muscle Loss With GLP-1s? - Medscape

What the report says

Medscape reported that the question of whether GLP-1-based medicines should raise concern about muscle loss was debated by two experts at the American Diabetes Association 2026 Scientific Sessions. The available public information does not identify the speakers, specify their positions, or describe any conclusions from the session, so the central confirmed development is that muscle preservation during GLP-1-associated weight loss was a formal topic of discussion at a major diabetes meeting.

The issue matters because GLP-1 receptor agonists and related incretin-based therapies are now widely used for type 2 diabetes and, in some formulations, chronic weight management. As patients lose substantial body weight, clinicians commonly assess not only fat loss but also possible reductions in lean mass, which includes skeletal muscle. That concern can be especially relevant for older adults, people with frailty, and patients who already have low muscle mass or limited physical function.

General clinical context, beyond the limited Medscape snippet, is that weight loss from any effective intervention can include some lean-mass reduction. The practical debate is usually not whether weight loss changes body composition, but how much muscle is lost, whether that loss affects strength or function, and what clinicians should do to reduce risk. Commonly discussed mitigation strategies include adequate protein intake, resistance exercise, and monitoring patients whose baseline health makes muscle loss more consequential.

Because the full Medscape article was not publicly available in the supplied material, this digest cannot attribute specific arguments, data, recommendations, or disagreements to the two experts. The report is best understood as highlighting an active clinical question accompanying the rapid uptake of GLP-1 therapies.